Polypeptide With Localisation/Targeting Motif TRIZ Cases

A cell-permeable polypeptide inhibits TRAF2 binding to CD40.

Engineered MCP and PCP proteins use hidden degrons to stabilize only when bound to RNA hairpin loops, reducing background fluorescence in live cell imaging.

Segmented polypeptide with flexible linker increases Rituximab sensitivity, reducing antibody consumption and cytokine storm risks in adoptive cell therapy.

CAR-T cells targeting CD19 deplete B cells, reducing side effects from systemic immunosuppression.

Targeted integration into the invariant CD3 locus eliminates random insertion variability and reduces tonic signaling in engineered T cells.

CD1a-targeting CAR T-cells eliminate cortical T-ALL blasts while sparing normal T-cells to prevent fratricide and immunodeficiency.

Lentiviral vectors express polypeptides combining alkaline phosphatase with bone-targeting moieties to deliver therapeutic enzymes.

Antibodies and CARs resolve targeting complexity by engaging T cells to destroy malignant cells.

Fusion protein restores mitochondrial respiration and normalizes reactive oxygen species levels in Barth syndrome by modifying cardiolipin.

A polypeptide antagonist targets the Na/K-ATPase/Src receptor complex to treat non-alcoholic steatohepatitis and hepatocellular carcinoma.

Synthetic eNOS decoy peptides bind Protein Kinase C to preserve endothelial cell barrier integrity against ventilator-induced lung injury.

Multicistronic lentiviral vector uses alternative splicing to switch between membrane-anchored and secreted antibody forms, reducing escape mutant risk.

Dasatinib modulates CAR-T cell kinase activity to prevent cytokine release syndrome while maintaining antitumor efficacy.

Fusion molecules link cytokines to phosphatidylserine ligands, redirecting immunosuppressive signals into localized immune activation.

Single variable domains achieve 100% bispecific activity while binding serum albumin to overcome rapid clearance and improve stability.

A leucine zipper variant with specific amino acid substitutions binds HDM2 and HDMX proteins to block p53 degradation.

CAR-T therapy selectively eliminates B cells producing autoantibodies, reducing toxicity and side effects associated with conventional immunosuppressants.

A fusion protein uses a Salmonella SptP fragment to translocate cargo into eukaryotic cell cytosols.

Peptide inhibitors block the OCA-B and Jmjd1a interaction to reduce pathogenic T cell function in Type 1 diabetes without global immune deregulation.

Engineered polypeptides with modified Fab constant regions and protein G binding domains resolve low Fab affinity limitations in purification processes.

Fusing TATk peptides to CDKL5 enables neuronal delivery, improving motor and cognitive functions while managing treatment complexity.

DNA expression vectors with mutant toxO operators produce monomeric diphtheria toxin fusion proteins.

Specific peptides bind connexin43 markers on senescent chondrocytes to eliminate these cells and promote healthy tissue re-differentiation.

A polynucleotide system uses a hook protein fused to a retention peptide and a binding domain to modulate intracellular trafficking of secretory proteins.

CD27 antibody depletes regulatory T-cells to enhance transferred T-cell persistence while avoiding neutropenia from chemotherapy conditioning.

Humanized antibodies target the IL-7 receptor extracellular domain to deplete malignant cells without interfering with signaling pathways.

Cpf1 endonuclease guides AAV vectors to precisely integrate chimeric antigen receptors, avoiding insertional oncogenesis risks.

A nucleic acid construct encodes a secretory transcription factor that moves therapeutic proteins across cell membranes.

Engineered TALENs cleave HIV-1 proviral DNA to eradicate latent virus without triggering cytokine storms.

Chimeric protein constructs deliver CARs to tumor cells via clathrin-mediated endocytosis, bypassing invasive cell extraction procedures.

Transgenic silkworms produce pentameric C-reactive protein without complex purification steps required by bacterial hosts.

Modified envelope glycoproteins reduce cellular toxicity and complement-mediated inactivation while maintaining sufficient viral titers for gene therapy.

Kinase inhibitors modify the solid tumor microenvironment to enable CAR-T cell infiltration and improve therapeutic efficacy.

Linking CD137 and CD3zeta domains in a recombinant CAR gene overcomes suboptimal T cell function for targeted CD30-positive tumor killing.

An ER-anchored TurboID fusion protein selectively biotinylates secretory proteins within the endoplasmic reticulum lumen.

Inducible promoters control expression timing to resolve the trade-off between high-yield scaffold assembly and cellular toxicity.

Humanized F77 antibodies bind glycolipid antigens on prostate cancer cells to enable targeted therapy.

Inhibiting innate immune responses with BX795 or 2-Aminopurine enhances primary T lymphocyte transduction efficiency.

Anti-target CAR T cells eliminate suppressive regulatory T cells in the tumor microenvironment, reducing cytokine release syndrome and neurologic toxicity.

Peptides bind Dpy-30 domains with high affinity, avoiding RIIa cross-reactivity.

A chimeric antigen receptor targets human CD45RC to induce apoptosis in pathogenic T cells.

Replacing native signals with optimized heterologous sequences boosts antigen expression levels, resolving insufficient immune response induction.

Voltage-gated calcium channels trigger transcription factor binding sites to synthesize therapeutic proteins in situ, bypassing lengthy vaccine development cycles.

Substituting wild-type transmembrane regions with E. coli-derived domains anchors P450 enzymes, eliminating cellular stress and boosting chemical productivity.

Chimeric antigen receptors integrate CTLA4 or PD-1 transmembrane domains to resolve signal complexity while regulating immune responses.

Engineered CAR T cells target solid tumors by binding specific antigens, sparing normal tissues and reducing side effects from conventional treatments.